Caplin Point Laboratories Limited has informed the Exchange regarding 'Intimation of Press Release on Acquisition of ANDAs'.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories, through its subsidiaries Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL), has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for Injectable and Ophthalmic products from a leading multinational generic manufacturer. The addressable market for these products is $473.2 million for the 12-month period ending August 2025. The portfolio includes select oncology injectables, which will be commercialized from the company's new dedicated oncology facility in Kakkalur. Of the 10 ANDAs, 5 have been acquired by Caplin One Labs Limited. The company plans to extend these products to non-U.S. markets including Mexico, Canada, the European Union, and Brazil. The Chairman described the U.S. market as a key growth engine and said this acquisition meaningfully accelerates the company's strategy in the region.
This is a positive development for shareholders as it expands Caplin Point's U.S. portfolio and adds oncology products to its pipeline, strengthening its growth prospects in regulated markets and potentially boosting future revenues.